Prephase treatment in elderly DLBC
- Conditions
- Diseases of the blood and blood -forming organs and certain disorders involving the immune mechanism
- Registration Number
- KCT0003916
- Lead Sponsor
- Kosin University Gospel Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 37
1)Extensive, histologically diagnosed, large B-cell lymphoma patients.
2) Age 65 or older at the time of diagnosis
3) Patients planning R-CHOP chemotherapy
4) Second Ann Arbor weapon (bulky = Diameter of 7cm), third or fourth patient
5) High intermediate or high risk with International Prognostic Index (IPI)
6) Patients who do not have a history of lymphoma before
7) Patients who decide to participate in this study voluntarily and agree in writing
1) CD20-positive widespread histological subtype other than large B-cell lymphoma
2) Patients with extensive B-cell lymphoma invading the central nervous system
3) A systemic disease in which anti-cancer drugs are administered is inappropriate
A. Patients who had clinically significant heart disease (hypertensioned congestive heart failure, syndrome coronary heart disease, cardiac arrhythmia) or myocardial infarction within the past six months.
B. Severe neurological and psychiatric disorders
C. Severe Active Infection
D. A medical condition that is difficult to perform other clinical trials.
4) If the drug used in this study is allergic to it
5) Failure to understand or disagree with written consent
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method treatment-related mortality rate; TRM
- Secondary Outcome Measures
Name Time Method IMWG(International Myeloma Working Group) fragility score before and after pre-phase treatment;TRM and RR according to IMWG(International Myeloma Working Group) fragility score;response rate; RR;safety;Incidence of neutropenic fever